JP2018532403A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532403A5
JP2018532403A5 JP2018516030A JP2018516030A JP2018532403A5 JP 2018532403 A5 JP2018532403 A5 JP 2018532403A5 JP 2018516030 A JP2018516030 A JP 2018516030A JP 2018516030 A JP2018516030 A JP 2018516030A JP 2018532403 A5 JP2018532403 A5 JP 2018532403A5
Authority
JP
Japan
Prior art keywords
composition
item
tissue
guide rna
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018516030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053960 external-priority patent/WO2017058793A1/en
Publication of JP2018532403A publication Critical patent/JP2018532403A/ja
Publication of JP2018532403A5 publication Critical patent/JP2018532403A5/ja
Pending legal-status Critical Current

Links

JP2018516030A 2015-09-29 2016-09-27 送達方法および組成物 Pending JP2018532403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234340P 2015-09-29 2015-09-29
US62/234,340 2015-09-29
PCT/US2016/053960 WO2017058793A1 (en) 2015-09-29 2016-09-27 Delivery methods and compositions

Publications (2)

Publication Number Publication Date
JP2018532403A JP2018532403A (ja) 2018-11-08
JP2018532403A5 true JP2018532403A5 (https=) 2019-10-31

Family

ID=58408949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516030A Pending JP2018532403A (ja) 2015-09-29 2016-09-27 送達方法および組成物

Country Status (8)

Country Link
US (1) US20170087224A1 (https=)
EP (1) EP3355954A4 (https=)
JP (1) JP2018532403A (https=)
CN (1) CN108601883A (https=)
AU (1) AU2016332704A1 (https=)
CA (1) CA2999922A1 (https=)
HK (1) HK1258900A1 (https=)
WO (1) WO2017058793A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
JP7287888B2 (ja) 2016-06-27 2023-06-06 ギャラリー，インコーポレイテッド ジェネレータ、電極付きのカテーテル、及び肺通路の治療方法
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
DK4218641T3 (da) 2017-12-26 2025-08-18 Galvanize Therapeutics Inc Optimering af energilevering til forskellige anvendelser
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020015279A1 (zh) * 2018-07-17 2020-01-23 杭州观梓健康科技有限公司 一种在干细胞中进行基因定向敲入的方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220001027A1 (en) * 2018-11-15 2022-01-06 President And Fellows Of Harvard College Genetically Engineered Skin Cells for the Systemic In Vivo Treatment of Deficient Enzymes, Factors or Proteins
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
WO2020192680A1 (en) * 2019-03-25 2020-10-01 The Chinese University Of Hong Kong Determining linear and circular forms of circulating nucleic acids
US11879892B2 (en) * 2019-04-08 2024-01-23 Velanidi Technologies LLC System, apparatus and method for sensing, detecting and effecting in a micro-to-nano environment
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP7551648B2 (ja) 2019-04-18 2024-09-17 ガルヴァナイズ セラピューティクス，インコーポレイテッド 異常組織を治療するための器械、及びシステム、
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
WO2021243270A1 (en) * 2020-05-29 2021-12-02 Georgia Tech Research Corporation Devices, systems, and methods for facilitating tissue delivery of drug
CN116829691A (zh) * 2020-08-04 2023-09-29 盖能适治疗股份有限公司 分子到体内细胞的脉冲电场转移
CA3188372A1 (en) * 2020-08-04 2022-02-10 Galvanize Therapeutics, Inc. Pulsed electric field transfer of molecules to cells while in the body
CN112807273B (zh) * 2021-02-23 2022-06-17 浙江大学 一种治疗炎症性皮肤病的基因编辑微针及其应用
JP2023094496A (ja) * 2021-12-23 2023-07-05 委子 陌間 抗菌・ウイルス治療薬の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713291B2 (en) * 1999-01-28 2004-03-30 Alan D. King Electrodes coated with treating agent and uses thereof
CA2452653A1 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
EP3594333B1 (en) * 2010-02-08 2023-11-01 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
WO2011109735A2 (en) * 2010-03-05 2011-09-09 Cornell University Ultrasound-assisted convection enhanced delivery of compounds in vivo with a transducer cannula assembly
BR112016013207A2 (pt) * 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
JP2017506893A (ja) * 2014-02-18 2017-03-16 デューク ユニバーシティ ウイルス複製不活化組成物並びにその製造方法及び使用
EP3149171A1 (en) * 2014-05-30 2017-04-05 The Board of Trustees of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
US20160346360A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
CA3015353A1 (en) * 2016-02-25 2017-08-31 Agenovir Corporation Viral and oncoviral nuclease treatment

Similar Documents

Publication Publication Date Title
JP2018532403A5 (https=)
Yadav et al. Biomedical applications of nanomaterials in the advancement of nucleic acid therapy: mechanistic challenges, delivery strategies, and therapeutic applications
JP2018532403A (ja) 送達方法および組成物
JP2020043862A (ja) 潜伏性ウイルス感染を処置するための組成物および方法
JP2018516983A5 (https=)
JP2019508051A5 (https=)
Feng et al. Strategies for high-efficiency mutation using the CRISPR/Cas system
JP2018516984A5 (https=)
EP4180526A3 (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP4349978A3 (en) Cas9-dna targeting unit chimeras
CN104805078A (zh) 用于高效基因组编辑的rna分子的设计、合成及其应用
WO2018183808A9 (en) Antiviral therapeutic
Soriano Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Dai et al. Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
Jamehdor et al. Principles and applications of CRISPR toolkit in virus manipulation, diagnosis, and virus-host interactions
AU2019382824A8 (en) Method and means to deliver miRNA to target cells
Schmidt et al. 117. AAV-TRISPR–A Novel Versatile AAV vector kit for combinatorial CRISPR and RNAi expression
Bloom et al. Recent advances in use of gene therapy to treat hepatitis B virus infection
CN102206680A (zh) 基于短链核酸片段的基因电转染缓冲液及其制备和应用方法
Sharaf-Eldin Technologies of gene editing and related clinical trials for the treatment of genetic and acquired diseases: a systematic review
Srivastava et al. Recent gene therapy approaches for the treatment of tuberculosis
Lin Application of CRISPR-Cas system in the treatment of human viral disease
CN104404076A (zh) 利用锌指核酸酶敲除人乳头瘤病毒e6e7基因的方法
Kharwade et al. CRISPR-Cas9 in Drug Discovery: Potential Applications and Ethical consideration
TIMINOUNI et al. Gene Editing Technology in the Treatment of Cancers and other Genetic Disorders